相似文献
1
Pharmacologic biomarkers in the development of stratified cancer medicine.
Clin Cancer Res. 2014 May 15;20(10):2525-9. doi: 10.1158/1078-0432.CCR-14-0511.
2
Pharmacodynamic biomarkers: falling short of the mark?
Clin Cancer Res. 2014 May 15;20(10):2587-94. doi: 10.1158/1078-0432.CCR-13-3132.
3
Implementation of validated pharmacodynamic assays in multiple laboratories: challenges, successes, and limitations.
Clin Cancer Res. 2014 May 15;20(10):2578-86. doi: 10.1158/1078-0432.CCR-14-0476.
4
Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics in the Era of Targeted Therapies.
Am Soc Clin Oncol Educ Book. 2016;35:e175-84. doi: 10.1200/EDBK_159061.
5
Blood Worth Bottling: Circulating Tumor DNA as a Cancer Biomarker.
Cancer Res. 2016 Oct 1;76(19):5590-5591. doi: 10.1158/0008-5472.CAN-16-2281.
6
Liquid biopsy: will it be the 'magic tool' for monitoring response of solid tumors to anticancer therapies?
Curr Opin Oncol. 2015 Nov;27(6):560-7. doi: 10.1097/CCO.0000000000000223.
7
Translating metastasis-related biomarkers to the clinic--progress and pitfalls.
Nat Rev Clin Oncol. 2013 Mar;10(3):169-79. doi: 10.1038/nrclinonc.2013.4. Epub 2013 Feb 5.
8
Circulating DNA biomarkers: a primer for metastatic colorectal cancer?
Lancet Oncol. 2015 Aug;16(8):878-9. doi: 10.1016/S1470-2045(15)00061-3. Epub 2015 Jul 13.
9
Pharmacodynamic Modeling of CDK4/6 Inhibition-Related Biomarkers and the Characterization of the Relationship Between Biomarker Response and Progression-Free Survival in Patients With Advanced Breast Cancer.
J Clin Pharmacol. 2022 Mar;62(3):376-384. doi: 10.1002/jcph.1971. Epub 2021 Nov 16.
10
Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.
Cancer J. 2009 Sep-Oct;15(5):406-20. doi: 10.1097/PPO.0b013e3181bd0445.
引用本文的文献
1
Biomarkers as Biomedical Bioindicators: Approaches and Techniques for the Detection, Analysis, and Validation of Novel Biomarkers of Diseases.
Pharmaceutics. 2023 May 31;15(6):1630. doi: 10.3390/pharmaceutics15061630.
2
Shortwave infrared emitting multicolored nanoprobes for biomarker-specific cancer imaging in vivo.
BMC Cancer. 2020 Nov 10;20(1):1082. doi: 10.1186/s12885-020-07604-8.
3
Shear induced carboplatin binding within the cavity of a phospholipid mimic for increased anticancer efficacy.
Sci Rep. 2015 May 22;5:10414. doi: 10.1038/srep10414.
本文引用的文献
1
Pharmacodynamic biomarkers: falling short of the mark?
Clin Cancer Res. 2014 May 15;20(10):2587-94. doi: 10.1158/1078-0432.CCR-13-3132.
2
Implementation of validated pharmacodynamic assays in multiple laboratories: challenges, successes, and limitations.
Clin Cancer Res. 2014 May 15;20(10):2578-86. doi: 10.1158/1078-0432.CCR-14-0476.
3
In vivo imaging as a pharmacodynamic marker.
Clin Cancer Res. 2014 May 15;20(10):2569-77. doi: 10.1158/1078-0432.CCR-13-2666.
4
Circulating tumor cells: a multifunctional biomarker.
Clin Cancer Res. 2014 May 15;20(10):2553-68. doi: 10.1158/1078-0432.CCR-13-2664.
5
Genome-wide association study: a useful tool to identify common genetic variants associated with drug toxicity and efficacy in cancer pharmacogenomics.
Clin Cancer Res. 2014 May 15;20(10):2541-52. doi: 10.1158/1078-0432.CCR-13-2755.
6
Using pharmacogene polymorphism panels to detect germline pharmacodynamic markers in oncology.
Clin Cancer Res. 2014 May 15;20(10):2530-40. doi: 10.1158/1078-0432.CCR-13-2780.
7
Evidence of clinical utility: an unmet need in molecular diagnostics for patients with cancer.
Clin Cancer Res. 2014 Mar 15;20(6):1428-44. doi: 10.1158/1078-0432.CCR-13-2961.
8
Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer.
Sci Transl Med. 2014 Feb 19;6(224):224ra26. doi: 10.1126/scitranslmed.3007947.
9
Detection of circulating tumor DNA in early- and late-stage human malignancies.
Sci Transl Med. 2014 Feb 19;6(224):224ra24. doi: 10.1126/scitranslmed.3007094.
10
Liquid biopsies: genotyping circulating tumor DNA.
J Clin Oncol. 2014 Feb 20;32(6):579-86. doi: 10.1200/JCO.2012.45.2011. Epub 2014 Jan 21.
Zotero 插件